These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34400415)

  • 1. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
    Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
    Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
    Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
    Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M; Shen C; Chen Y; Chen Z; Zhou K; Chen Y; Li W; Zeng C; Qing Y; Wu D; Xu C; Tang T; Che Y; Qin X; Xu Z; Wang K; Leung K; Sau L; Deng X; Hu J; Wu Y; Chen J
    Cell Rep Med; 2024 Jul; 5(7):101645. PubMed ID: 39019012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
    Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability of FLT3 inhibitors: how do we use them?
    Perl AE
    Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
    Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
    Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Carranza-Aranda AS; Jave-Suárez LF; Flores-Hernández FY; Huizar-López MDR; Herrera-Rodríguez SE; Santerre A
    Mol Med Rep; 2024 Dec; 30(6):. PubMed ID: 39392050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
    Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T
    Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.
    Patel AB; Pomicter AD; Yan D; Eiring AM; Antelope O; Schumacher JA; Kelley TW; Tantravahi SK; Kovacsovics TJ; Shami PJ; O'Hare T; Deininger MW
    Leukemia; 2020 Nov; 34(11):2981-2991. PubMed ID: 32409689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of quizartinib in the treatment of acute myeloid leukemia.
    Ostronoff F; Estey E
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
    Weisberg E; Meng C; Case AE; Sattler M; Tiv HL; Gokhale PC; Buhrlage SJ; Liu X; Yang J; Wang J; Gray N; Stone RM; Adamia S; Dubreuil P; Letard S; Griffin JD
    Br J Haematol; 2019 Nov; 187(4):488-501. PubMed ID: 31309543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
    Sexauer A; Perl A; Yang X; Borowitz M; Gocke C; Rajkhowa T; Thiede C; Frattini M; Nybakken GE; Pratz K; Karp J; Smith BD; Levis M
    Blood; 2012 Nov; 120(20):4205-14. PubMed ID: 23012328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 19. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
    Hu C; Zhang Y; Yang J; Xu Y; Deng T; Li Y; Xu S; Wang S; Wang P
    Cell Commun Signal; 2024 Jul; 22(1):355. PubMed ID: 38978049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of
    Kondo T; Onozawa M; Fujisawa S; Harada S; Ogasawara R; Izumiyama K; Saito M; Morioka M; Mori A; Teshima T
    Hematology; 2021 Dec; 26(1):256-260. PubMed ID: 33631087
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.